You are here: Home » 2021 » January » Archives for 26th

Telefónica Germany selects Opanga Networks Inc for RAN Optimization

MUNICH, Germany, Jan. 26, 2021 (GLOBE NEWSWIRE) — Telefnica Germany GmbH & Co. OHG announced that it has selected Seattle based Opanga Networks, Inc as its RAN Optimization partner in Germany. "Mobile Network performance is under intensifying strain from the continual growth in data traffic," said Jochen Bockfeld, Director Core & Network Services at Telefnica Germany. "RAN Optimization software, that can be deployed rapidly in the mobile core, is mission critical to our being able to provide the best–in–class mobile experience for our customers."

Opanga's highly innovative software solutions are founded on advanced machine learning techniques that provide immediate benefit to mobile network customer experience. When Opanga's software is deployed, the network runs much faster to sustain the best possible user experience.

"We are very proud to call Telefnica Germany our customer," said Ben Hadorn, Head of European Operations for Opanga Networks. "Telefnica Germany is a flagship operator as well as an innovation leader in our industry and our solutions will be pivotal in helping the Telefnica team sustain the very best possible experience for their customers."

As the Mobile Core migrates to the cloud, new opportunities to leverage innovative software technologies incorporating state of the art machine learning become available to network designers. The mobile industry is at a vital point where innovation and software must augment the "build a bigger" network approach.

About Telefnica Germany

Telefnica Germany offers telecommunication services for private and business customers as well as innovative digital products and services in the field of Internet of Things and data analysis. The company is one of the leading integrated telecommunications providers in Germany. In mobile communications alone, Telefnica Germany / O2 manages more than 42.7 million connections without M2M (as of 30.09.2020) – no other network operator connects more people in Germany. Under the core brand O2 as well as various second and partner brands, the company sells post– and prepaid mobile products with innovative mobile data services. The basis for this is the mobile network based on a highly resilient GSM, UMTS and LTE infrastructure. At the same time, the company is building a powerful and energy–efficient 5G network. Telefnica Germany also provides telephony and high–speed Internet products based on different technologies in the fixed network area. Telefnica Deutschland Holding AG has been listed in the Prime Standard on the Frankfurt Stock Exchange (TecDAX) since 2012. In the 2019 financial year the company generated sales of 7.4 billion euros with almost 8,500 employees. The company is majority–owned by the Spanish telecommunications group Telefnica S.A. with headquarters in Madrid. With business activities in 14 countries and a customer base of around 350 million lines, the group is one of the largest telecommunications providers in the world.

About Opanga Networks

Opanga Networks is a software solutions company focused on developing products which make mobile networks much more efficient, faster and capable of ultra–high performance. Our products are installed in the mobile core, dramatically accelerating Radio Access Network (RAN) performance. Opanga solutions elevate QoE by relieving congestion on cell sites which are overburdened with unrelenting growth of data traffic. Opanga offers the only ultra–high RAN performance solutions which can be deployed network–wide in a matter of hours.

For more information, please contact Opanga Networks at lightningfastmobile@opanga.com


GLOBENEWSWIRE (Distribution ID 8142224)

Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)

PRESS RELEASE

Nyxoah announces full–body 1.5T and 3T MRI compatibility for the Genio system to treat Obstructive Sleep Apnea (OSA)

Mont–Saint–Guibert, Belgium "" 26th January, 2021 "" Nyxoah SA (Euronext: NYXH) ("Nyxoah" or the "Company"), a health–technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has received CE Mark Magnetic Resonance Imaging (MRI) conditional labeling for the current Genio neurostimulation–based OSA therapy to treat Obstructive Sleep Apnea.

This revised labeling ensures that patients who receive the Genio system and those already implanted can now undergo full–body 1.5T and 3T MRI diagnostic scans within approved parameters and access the benefits of Genio unique bilateral stimulation therapy.

Olivier Taelman, Chief Executive Officer of Nyxoah, commented: "We are delighted to announce full–body 1.5T and 3T MR conditional CE mark approval for the Genio system, resulting from the unique and unparalleled design of our technology. Such an extensive labeling is unique to Nyxoah in the field of neurostimulation–based OSA therapies. Currently other therapies cannot fully address this need due to limitations to 1.5T MRI scans and body areas exclusion. As a company, Nyxoah always puts the patient first and seeks to ensure minimal disruption of their daily life and optimal Quality of Life (QOL)."

Prof. Dr. Clemens Heiser, MD, MHBA, PhD, ENT surgeon from Klinikum Rechts der Isar "" Munich added: "Prevalence of MRI scans as diagnostic modality is growing, especially for OSA patients, as this condition is being associated with increased risk of comorbidities, such as cardiovascular diseases. The addition of 1.5T and 3T full–body MR conditional labeling for the Genio system will be another critical benefit for my patients and will help me ensure those who may need an MRI can benefit from Nyxoah's innovations with no fear for themselves and their implant during the exam".

– ENDS –

For further information, please contact:

Nyxoah
Milena Venkova, Corporate Communications Manager
milena.venkova@nyxoah.com
+32 490 11 93 57

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a CE–validated, patient–centered, next generation hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk1 and comorbidities including cardiovascular diseases, depression and stroke.
Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post–marketing EliSA study in Europe to confirm the long–term safety and efficacy of the Genio system.
For more information, please visit www.nyxoah.com.

Caution "" Genio is CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

1 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen–Year Follow–up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071""1078.

Attachment


GLOBENEWSWIRE (Distribution ID 1000452644)